Celluris

Celluris is a Swiss-Brazilian biotech startup at the forefront of bringing CAR-T cell therapy to Latin America. As a pioneer in the region, it is developing personalized immunotherapies for a range of cancers by genetically modifying a patient's own T-cells to target tumors. The company has established key research partnerships and is advancing its pipeline, positioning itself to address a significant unmet medical need with potentially transformative treatments. Its strategic location bridges European biotech innovation with the clinical and market opportunities in Brazil.

Autologous CAR-T cell therapy platform for personalized cancer immunotherapy, with development focused on adaptation for the Latin American market.

Celluris is a first-mover in Latin America with no direct local competitors in CAR-T development. Its primary competition comes from global pharmaceutical companies (e.g., Novartis, Gilead) whose approved CAR-T products are extremely high-cost and imported, and from future potential entrants. Its competitive edge is localized development, cost-structure potential, and regional expertise.